Aspirin-Exacerbated Respiratory Disease (AERD)
The most likely diagnosis is aspirin-exacerbated respiratory disease (AERD), also known as NSAID-induced bronchospasm, given the acute onset of wheezing and dyspnea within one hour of ibuprofen ingestion in a patient with pre-existing asthma and rhinitis. 1
Clinical Reasoning
Key Diagnostic Features Supporting AERD
The clinical presentation is classic for NSAID-induced bronchospasm:
- Temporal relationship: Acute respiratory symptoms developed within one hour of ibuprofen ingestion, consistent with the typical 20 minutes to 3 hours onset window for AERD 2
- Pre-existing risk factors: The patient has mild intermittent asthma and chronic rhinitis, which are established risk factors for aspirin-exacerbated respiratory disease 1
- Mechanism: This reaction results from COX-1 inhibition by NSAIDs (including ibuprofen), causing shunting of arachidonic acid down the leukotriene pathway, leading to bronchoconstriction 1
- Prevalence: AERD occurs in 8-21% of adults with asthma, with higher rates in those with chronic rhinitis 1, 2
Why Other Diagnoses Are Less Likely
Acute pericardial tamponade is unlikely because:
- Normal chest X-ray (tamponade typically shows enlarged cardiac silhouette) 1
- Bilateral wheezing is not a feature of tamponade
- Low-voltage QRS can occur with obesity (BMI 36) due to increased chest wall thickness, not necessarily indicating pericardial effusion 1
Pneumothorax is excluded by:
- Normal chest X-ray 1
- Bilateral breath sounds present on examination 1
- Diffuse bilateral wheezing (pneumothorax would cause unilateral decreased breath sounds) 1
Acute diastolic heart failure is less likely because:
- Only mild bilateral edema (1+) 1
- Normal chest X-ray without pulmonary edema 1
- The acute temporal relationship with NSAID ingestion better explains the presentation 1
Clinical Implications and Management
Immediate Actions
- Discontinue ibuprofen immediately and avoid all NSAIDs, as there is high cross-reactivity among COX-1 inhibitors 1, 3
- Initiate bronchodilator therapy with short-acting beta-2 agonists (patient already has albuterol inhaler) 1
- Consider systemic corticosteroids for moderate to severe exacerbation 1
Important Warnings from FDA Labeling
The ibuprofen FDA label specifically warns: "This symptom complex typically occurs in asthmatic patients who experience rhinitis with or without nasal polyps, or who exhibit severe, potentially fatal bronchospasm after taking aspirin or other NSAIDs. Since cross reactivity, including bronchospasm, between aspirin and NSAIDs has been reported in such aspirin-sensitive patients, ibuprofen tablets should not be administered to patients with this form of aspirin sensitivity and should be used with caution in patients with preexisting asthma." 3
Future Considerations
- Avoid all NSAIDs in this patient going forward 1, 3
- Alternative analgesics: Acetaminophen has low cross-reactivity and is safer, though not completely risk-free 1
- COX-2 selective inhibitors have lower (but not zero) cross-reactivity 1
- Aspirin desensitization may be considered if the patient has compelling cardiovascular indications requiring aspirin therapy, though this requires specialized protocols 1